In the clinical study focused on AML therapy with anti-CD33 CAR-T cells, significant side effects were detected, including cytokine storm, neurotoxicity, tumor lysis syndrome, and third-degree respiratory distress syndrome [36]. The gene discussed is CD33; the disease is acute myeloid leukemia.